REFERENCES
1. Heck JE, Meyers TJ, Lombardi C, et al. Case-control study of birth
characteristics and the risk of hepatoblastoma. Cancer Epidemiol .
2013;37(4):390-395.
2. Lopez-Terrada D, Alaggio R, de Davila MT, et al. Towards an
international pediatric liver tumor consensus classification:
proceedings of the Los Angeles COG liver tumors symposium. Mod
Pathol . 2014;27(3):472-491.
3. Howlader N, Noone A, Krapcho M, et al. SEER Cancer Statistics Review
1975-2013. Natl Cancer Inst . 2013.
4. Turcotte LM, Georgieff MK, Ross JA, et al. Neonatal medical exposures
and characteristics of low birth weight hepatoblastoma cases: a report
from the Children’s Oncology Group. Pediatr Blood Cancer .
2014;61(11):2018-2023.
5. Perilongo G, Malogolowkin M, Feusner J. Hepatoblastoma clinical
research: lessons learned and future challenges. Pediatr Blood
Cancer . 2012;59(5):818-821.
6. Trobaugh-Lotrario AD, Katzenstein HM. Chemotherapeutic approaches for
newly diagnosed hepatoblastoma: past, present, and future strategies.Pediatr Blood Cancer . 2012;59(5):809-812.
7. Pritchard J, Brown J, Shafford E, et al. Cisplatin, doxorubicin, and
delayed surgery for childhood hepatoblastoma: a successful
approach–results of the first prospective study of the International
Society of Pediatric Oncology. J Clin Oncol .
2000;18(22):3819-3828.
8. Douglass EG, Reynolds M, Finegold M et al. Cisplatin, vincristine,
and fluorouracil therapy for hepatoblastoma: A pediatric oncology group
study. J Clin Oncol . 1993;11(1):96-9.
9. Ortega JA, Douglass EC, Feusner JH, et al. Randomized comparison of
cisplatin/vincristine/fluorouracil and cisplatin/continuous infusion
doxorubicin for treatment of pediatric hepatoblastoma: A report from the
Children’s Cancer Group and the Pediatric Oncology Group. J Clin
Oncol . 2000;18(14):2665-2675.
10. Meyers RL, Czauderna P, Otte JB. Surgical treatment of
hepatoblastoma. Pediatr Blood Cancer . 2012;59(5):800-8
11. Weinberg AG, Finegold MJ. Primary hepatic tumors of childhood.Hum Pathol . 1983;14(6):512-537.
12. Ma X, Liu Y, Liu Y, et al. Pan-cancer genome and transcriptome
analyses of 1,699 paediatric leukaemias and solid tumours.Nature . 2018;555(7696):371-376.
13. Maschietto M, Rodrigues TC, Kashiwabara AY, et al. DNA methylation
landscape of hepatoblastomas reveals arrest at early stages of liver
differentiation and cancer-related alterations. Oncotarget . 2016;
17; 8(58): 97871–97889.
14. Yamada N, Yasui K, Dohi O, et al. Genome-wide DNA methylation
analysis in hepatocellular carcinoma. Oncol Rep .
2016;35(4):2228-2236.
15. Rivas MP, Aguiar TFM, Fernandes GR, et al. TET Upregulation Leads to
5-Hydroxymethylation Enrichment in Hepatoblastoma. Front Genet .
2019;10:1-7.
16. Maris JM, Denny CT. Focus on embryonal malignancies. Cancer
Cell . 2002;2(6):447-450.
17. Kim EH, Koh KN, Park M, et al. Clinical features of infantile
hepatic hemangioendothelioma. Korean J Pediatr . 2011;
54(6):260-6.
18. Okita K, Yamakawa T, Matsumura Y, et al. An efficient nonviral
method to generate integration-free human-induced pluripotent stem cells
from cord blood and peripheral blood cells. Stem Cells .
2013;31(3):458-466.
19. Hay DC, Zhao D, Fletcher J, et al. Efficient Differentiation of
Hepatocytes from Human Embryonic Stem Cells Exhibiting Markers
Recapitulating Liver Development In Vivo. Stem Cells .
2008;26(4):894-902.
20. Vandesompele J, De Preter K, Pattyn F, et al. Accurate normalization
of real-time quantitative RT-PCR data by geometric averaging of multiple
internal control genes. Genome Biol . 2002;3(7).
21. Livak KJ, Schmittgen TD. Analysis of relative gene expression data
using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method.Methods . 2001;25(4):402-408.
22. Edmunds RC, McIntyre JK, Luckenbach JA, Baldwin DH, Incardona JP.
Toward enhanced MIQE compliance: reference residual normalization of
qPCR gene expression data. J Biomol Tech . 2014;25(2):54-60.
23. Hardeo S, Mohammed AI. The Analysis of Variance: Fixed, Random
and Mixed Models . Birkhauser; 2000.
24. Fabregat A, Sidiropoulos K, Viteri G, et al. Reactome pathway
analysis: A high-performance in-memory approach. BMC
Bioinformatics . 2017;18(1):142.
25. Fabregat A, Sidiropoulos K, Garapati P, et al. The reactome pathway
knowledgebase. Nucleic Acids Res . 2016;44(D1):D481-D487.
26. Aguiar TFM, Rivas MP, Costa S, et al. Insights Into the Somatic
Mutation Burden of Hepatoblastomas From Brazilian Patients. Front
Oncol . 2020;10:556.
27. Meyers RL, Maibach R, Hiyama E, et al. Risk-stratified staging in
paediatric hepatoblastoma: a unified analysis from the Children’s
Hepatic tumors International Collaboration. Lancet Oncol .
2017;18(1):122-131.
28. Czauderna P, Haeberle B, Hiyama E, et al. The Children’s Hepatic
tumors International Collaboration (CHIC): Novel global rare tumor
database yields new prognostic factors in hepatoblastoma and becomes a
research model. Eur J Cancer . 2016;52:92-101.
29. Cairo S, Armengol C, De Reynies A, et al. Hepatic stem-like
phenotype and interplay of Wnt/beta-catenin and Myc signaling in
aggressive childhood liver cancer. Cancer Cell .
2008;14(6):471-484.
30. Sumazin P, Chen Y, Trevino LR, et al. Genomic analysis of
hepatoblastoma identifies distinct molecular and prognostic subgroups.Hepatology . 2017;65(1):104-121.
31. Houssaint E. Differentiation of the mouse hepatic primordium. I. An
analysis of tissue interactions in hepatocyte differentiation.Cell Differ . 1980; 9(5):269-79
32. Medlock ES, Haar JL. The liver hemopoietic environment: I.
Developing hepatocytes and their role in fetal hemopoiesis. Anat
Rec . 1983; 207(1):31-41.
33. Zorn. Liver Development. StemBook . 2008.
34. Mudbhary R, Hoshida Y, Chernyavskaya Y, et al. UHRF1 Overexpression
Drives DNA Hypomethylation and Hepatocellular Carcinoma. Cancer
Cell . 2014;25(2):196-209.
35. Lau HH, Ng NHJ, Loo LSW, Jasmen JB, Teo AKK. The molecular functions
of hepatocyte nuclear factors – In and beyond the liver. J
Hepatol . 2018;68(5):1033-1048.
36. Combes AN, Whitelaw E. Epigenetic reprogramming: Enforcer or enabler
of developmental fate? Dev Growth Differ . 2010; 52(6):483-91
37. Carrillo-Reixach J, Torrens L, Simon-Coma M, et al. Epigenetic
footprint enables molecular risk stratification of hepatoblastoma with
clinical implications. J Hepatol . March 2020;
30;S0168-8278(20)30187-2.
38. Aguiar TFM, Carneiro TN, da Costa CML, Rosenberg C, da Cunha IW,
Krepischi ACV. The genetic and epigenetic landscapes of hepatoblastomas.Appl Cancer Res . 2017; (37),20.
39. Eichenmüller M, Trippel F, Kreuder M, et al. The genomic landscape
of hepatoblastoma and their progenies with HCC-like features. J
Hepatol . 2014;61(6):1312-1320.
40. Rodrigues TC, Fidalgo F, da Costa CML, et al. Upregulated genes at
2q24 gains as candidate oncogenes in hepatoblastomas. Future
Oncol . 2014;10(15):2449-2457.
41. Gröbner SN, Worst BC, Weischenfeldt J, et al. The landscape of
genomic alterations across childhood cancers. Nature .
2018;555(7696):321-327.
42. Cui X, Liu B, Zheng S, Dong K, Dong R. Genome-wide analysis of DNA
methylation in hepatoblastoma tissues. Oncol Lett .
2016;12(2):1529-1534.
43. Czauderna P, Lopez-Terrada D, Hiyama E, Haberle B, Malogolowkin MH,
Meyers RL. Hepatoblastoma state of the art: pathology, genetics, risk
stratification, and chemotherapy. Curr Opin Pediatr .
2014;26(1):19-28.
44. Marin JJG, Cives-Losada C, Asensio M, Lozano E, Briz O, Macias RIR.
Mechanisms of anticancer drug resistance in hepatoblastoma.Cancers (Basel) . 2019;11(3).
45. Kawashiro T, Yamashita K, Zhao XJ, et al. A study on the metabolism
of etoposide and possible interactions with antitumor or supporting
Agents by Human Liver Microsomes. J Pharmacol Exp Ther .
1998;286(3):1294-1300.
46. Lagas JS, Fan L, Wagenaar E, et al. P-glycoprotein (P-gp/Abcb1),
Abcc2, and Abcc3 determine the pharmacokinetics of etoposide. Clin
Cancer Res . 2010;16(1):130-140.
47. Ghassabian S, Rawling T, Zhou F, et al. Role of human CYP3A4 in the
biotransformation of sorafenib to its major oxidized metabolites.Biochem Pharmacol . 2012;84(2):215-223.
48. Martino E, Casamassima G, Castiglione S, et al. Vinca alkaloids and
analogues as anti-cancer agents: Looking back, peering ahead.Bioorganic Med Chem Lett . 2018;28(17):2816-2826.
49. Sarper N, Çorapçoǧlu F, Ank Y, Ural D, Yldz K, Tugay M. Unresectable
multifocal hepatoblastoma with cardiac extension: Excellent response
with HB-94 chemotherapy protocol. J Pediatr Hematol Oncol .
2006;28(6):386-390.
50. Hiyama E, Hishiki T, Watanabe K, et al. Resectability and tumor
response after preoperative chemotherapy in hepatoblastoma treated by
the Japanese Study Group for Pediatric Liver Tumor (JPLT)-2 protocol.J Pediatr Surg . 2016;51(12):2053-2057.
51. Cacciavillano WD, Brugières L, Childs M, et al. Phase II study of
high-dose cyclophosphamide in relapsing and/or resistant hepatoblastoma
in children: A study from the SIOPEL group. Eur J Cancer .
2004;40(15):2274-2279.